Safety and Preliminary Efficacy of hUCMSC-EVs in Interstitial Lung Disease

Key Inclusion Criteria:

• Age 18 years and older, regardless of gender.
• Diagnosed with interstitial lung disease (ILD).
• High-resolution computed tomography (HRCT) findings within 3 months prior to randomization must be consistent with interstitial pulmonary imaging changes.
• Pulmonary function test within the protocol-defined acceptable range prior to randomization.
• Good compliance, able to understand and cooperate with the required examinations and procedures, and willing to attend follow-up visits as scheduled.
• Voluntary participation and signing of written informed consent form.

Key Exclusion Criteria:

• Inability to tolerate nebulized inhalation therapy.
• Requirement for oxygen supplementation > 15 hours per day during the screening period.
• Allergic diathesis or a history of life-threatening drug hypersensitivity.
• History of malignancy within 5 years.
• Active hepatitis B, hepatitis C, or HIV infection.
• Active systemic infection requiring antibiotic therapy.
• Clinically significant laboratory abnormalities at screening.
• Concomitant significant or severe respiratory disease.
• History of psychiatric illness, epilepsy, or other central nervous system disorders.
• Concomitant severe cardiovascular, hepatic, or renal systemic disease.
• Pregnancy, planned pregnancy in the near future, or breastfeeding.
• Unwillingness to use effective contraception during the study period.
• Any condition that, in the opinion of the investigator, may increase the risk to the participant or interfere with the study outcomes.